EA201490328A1 - Исследования для мониторинга нарушений свертываемости крови - Google Patents

Исследования для мониторинга нарушений свертываемости крови

Info

Publication number
EA201490328A1
EA201490328A1 EA201490328A EA201490328A EA201490328A1 EA 201490328 A1 EA201490328 A1 EA 201490328A1 EA 201490328 A EA201490328 A EA 201490328A EA 201490328 A EA201490328 A EA 201490328A EA 201490328 A1 EA201490328 A1 EA 201490328A1
Authority
EA
Eurasian Patent Office
Prior art keywords
coarding
studies
blood
monitoring disorders
present
Prior art date
Application number
EA201490328A
Other languages
English (en)
Other versions
EA028914B1 (ru
Inventor
Юрг Зоммер
Хайянь Цзян
Синь Чжан
Буюйэ Ян
Гленн Пирс
Original Assignee
Байоджен Айдек Хемофилия Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Хемофилия Инк. filed Critical Байоджен Айдек Хемофилия Инк.
Publication of EA201490328A1 publication Critical patent/EA201490328A1/ru
Publication of EA028914B1 publication Critical patent/EA028914B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/9645—Factor IX (3.4.21.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение обеспечивает способы дозирования химерных и гибридных полипептидов фактора VIII или фактора IX. Настоящее изобретение дополнительно обеспечивает высокочувствительные способы определения количества активированного белка FIX в тестируемом образце.
EA201490328A 2011-07-25 2012-07-25 Исследования для мониторинга нарушений свертываемости крови EA028914B1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161511207P 2011-07-25 2011-07-25
US201161522560P 2011-08-11 2011-08-11
US201161568986P 2011-12-09 2011-12-09
US201261596902P 2012-02-09 2012-02-09
US201261668911P 2012-07-06 2012-07-06
PCT/US2012/048191 WO2013016454A1 (en) 2011-07-25 2012-07-25 Assays to monitor bleeding disorders

Publications (2)

Publication Number Publication Date
EA201490328A1 true EA201490328A1 (ru) 2014-07-30
EA028914B1 EA028914B1 (ru) 2018-01-31

Family

ID=47601518

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490328A EA028914B1 (ru) 2011-07-25 2012-07-25 Исследования для мониторинга нарушений свертываемости крови

Country Status (4)

Country Link
US (2) US10656167B2 (ru)
EP (1) EP2737311B1 (ru)
EA (1) EA028914B1 (ru)
WO (1) WO2013016454A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
JP6317328B2 (ja) 2012-04-11 2018-04-25 ビオベラティブ テラポイティクス インコーポレーテッドＢｉｏｖｅｒａｔｉｖ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． グリコサミノグリカンを検出する方法
EP2877202A4 (en) * 2012-07-25 2016-06-01 Biogen Ma Inc BLOOD FACTOR MONITORING TEST AND USES THEREOF
EP3003368A4 (en) 2013-05-24 2017-05-03 Biogen MA Inc. Anti-gpiib/iiia antibodies or uses thereof
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
ES2967617T3 (es) * 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
TWI777175B (zh) 2015-11-13 2022-09-11 日商武田藥品工業股份有限公司 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
GB201614462D0 (en) * 2016-08-24 2016-10-05 Univ Sheffield Clotting factor
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
US7125841B2 (en) 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
HUP0401534A3 (en) 2001-09-04 2006-01-30 Merck Patent Gmbh Modified factor ix
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP2298347B1 (en) 2003-05-06 2015-09-30 Biogen Hemophilia Inc. Clotting factor chimeric proteins for treatment of a hemostatic disorder
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007103455A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
US20120178114A1 (en) * 2007-08-10 2012-07-12 Subc, Inc. Methods and devices for detecting thrombin generation
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
WO2009051717A2 (en) 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life
CA2721683A1 (en) 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
WO2009140015A2 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
WO2009130198A2 (en) 2008-04-21 2009-10-29 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
EP2149603A1 (en) * 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
JP5709316B2 (ja) * 2008-11-14 2015-04-30 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
US8498710B2 (en) 2009-07-28 2013-07-30 Nevro Corporation Linked area parameter adjustment for spinal cord stimulation and associated systems and methods
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
ES2880038T3 (es) 2009-12-06 2021-11-23 Bioverativ Therapeutics Inc Polipéptidos quiméricos e híbridos de factor VIII-Fc, y métodos de uso de los mismos
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
FI126269B (en) 2014-05-30 2016-09-15 Cellraid Ltd Determination and control of radiation exposure

Also Published As

Publication number Publication date
EP2737311A4 (en) 2015-04-01
US11747351B2 (en) 2023-09-05
US10656167B2 (en) 2020-05-19
US20200386774A1 (en) 2020-12-10
EP2737311A1 (en) 2014-06-04
WO2013016454A1 (en) 2013-01-31
US20150079072A1 (en) 2015-03-19
EP2737311B1 (en) 2020-12-02
EA028914B1 (ru) 2018-01-31

Similar Documents

Publication Publication Date Title
EA201490328A1 (ru) Исследования для мониторинга нарушений свертываемости крови
HK1201577A1 (en) Point-of care immunoassay for quantitative small analyte detection
ES2863778T8 (es) Procedimientos de ensayo para la determinación de la contribución de una fuente en una muestra
EA201270775A1 (ru) Связывающие сывороточный альбумин молекулы
CR20120371A (es) Antagonistas de pcsk9
CY1116719T1 (el) Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου
MX349561B (es) Método para detectar nucleosomas que contienen variantes de histonas.
EA201490999A1 (ru) Способ проведения количественных анализов
EP2826500A4 (en) CONTAINER FOR BLOOD ANALYSIS AND BLOOD SAMPLING INSTRUMENT
AT10541U2 (de) Vorrichtung zur bestimmung der konzentration von feststoffpartikeln
BRPI1008757A2 (pt) Emulsões de pufa de alta concentração
WO2010046443A3 (en) Methods for detection and diagnosis of a bone or cartilage disorder
MX336109B (es) Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
GB2517857A (en) Methods for detecting allosteric modulators of proteins
WO2012149145A3 (en) Ocular detection of amyloid proteins
BR112015008473A2 (pt) aparelho e método para determinar a quantidade de uma proteína alvo e/ou outros tipos de biomarcadores ou analitos presentes em uma amostra
CY1117838T1 (el) Παραγοντες προβλεψης για θεραπευτικη αγωγη καρκινου
GB201206977D0 (en) An enzyme detection device
EP2826499A4 (en) CONTAINER FOR THE STUDY OF BLOOD AND BLOOD DETECTION DEVICE
IN2015DN02927A (ru)
ZA201402460B (en) Assembly for determining the presence or absence of an analyte in a blood sample and analysis unit comprising such an assembly
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
EP2826501A4 (en) CONTAINER FOR BLOOD ANALYSIS AND BLOOD SAMPLING INSTRUMENT
WO2011130647A3 (en) Compositions and methods for characterizing a myopathy
EP2700950A4 (en) METHOD FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERACTIONS ON SINGLE-MOLECULAR LIFE IN A CELL ENVIRONMENT AND METHOD FOR MEASURING THE DENSITY OF PROTEINS ACTIVATED IN CYTOSOL

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): TJ TM